273 related articles for article (PubMed ID: 34986275)
1. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J
FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275
[TBL] [Abstract][Full Text] [Related]
2. The sphingosine-1-phosphate receptor 1 modulator ponesimod repairs cuprizone-induced demyelination and induces oligodendrocyte differentiation.
Willems E; Schepers M; Piccart E; Wolfs E; Hellings N; Ait-Tihyaty M; Vanmierlo T
FASEB J; 2024 Jan; 38(2):e23413. PubMed ID: 38243760
[TBL] [Abstract][Full Text] [Related]
3. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
[TBL] [Abstract][Full Text] [Related]
4. Visualizing Sphingosine-1-Phosphate Receptor 1(S1P
Hashemi E; Yoseph E; Tsai HC; Moreno M; Yeh LH; Mehta SB; Kono M; Proia R; Han MH
Cell Mol Neurobiol; 2023 Apr; 43(3):1219-1236. PubMed ID: 35917044
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.
Gatfield J; Monnier L; Studer R; Bolli MH; Steiner B; Nayler O
Cell Signal; 2014 Jul; 26(7):1576-88. PubMed ID: 24704119
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
7. S1P
Jonnalagadda D; Kihara Y; Rivera R; Chun J
eNeuro; 2021; 8(4):. PubMed ID: 33893167
[TBL] [Abstract][Full Text] [Related]
8. Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination.
Kim S; Bielawski J; Yang H; Kong Y; Zhou B; Li J
Glia; 2018 Mar; 66(3):654-669. PubMed ID: 29193293
[TBL] [Abstract][Full Text] [Related]
9. Siponimod (BAF312) Activates Nrf2 While Hampering NFκB in Human Astrocytes, and Protects From Astrocyte-Induced Neurodegeneration.
Colombo E; Bassani C; De Angelis A; Ruffini F; Ottoboni L; Comi G; Martino G; Farina C
Front Immunol; 2020; 11():635. PubMed ID: 32322257
[TBL] [Abstract][Full Text] [Related]
10. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
[TBL] [Abstract][Full Text] [Related]
11. Ponesimod for the treatment of relapsing multiple sclerosis.
Baldin E; Lugaresi A
Expert Opin Pharmacother; 2020 Nov; 21(16):1955-1964. PubMed ID: 32808832
[TBL] [Abstract][Full Text] [Related]
12. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis.
Musella A; Gentile A; Guadalupi L; Rizzo FR; De Vito F; Fresegna D; Bruno A; Dolcetti E; Vanni V; Vitiello L; Bullitta S; Sanna K; Caioli S; Balletta S; Nencini M; Buttari F; Stampanoni Bassi M; Centonze D; Mandolesi G
Cells; 2020 May; 9(5):. PubMed ID: 32455907
[TBL] [Abstract][Full Text] [Related]
13. Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data.
Ruggieri S; Quartuccio ME; Prosperini L
Degener Neurol Neuromuscul Dis; 2022; 12():61-73. PubMed ID: 35356493
[TBL] [Abstract][Full Text] [Related]
14. Ponesimod protects against neuronal death by suppressing the activation of A1 astrocytes in early brain injury after experimental subarachnoid hemorrhage.
Zhang L; Guo K; Zhou J; Zhang X; Yin S; Peng J; Liao Y; Jiang Y
J Neurochem; 2021 Aug; 158(4):880-897. PubMed ID: 34143505
[TBL] [Abstract][Full Text] [Related]
15. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
[TBL] [Abstract][Full Text] [Related]
16. FTY720 requires vitamin B
Jonnalagadda D; Kihara Y; Groves A; Ray M; Saha A; Ellington C; Lee-Okada HC; Furihata T; Yokomizo T; Quadros EV; Rivera R; Chun J
Cell Rep; 2023 Dec; 42(12):113545. PubMed ID: 38064339
[TBL] [Abstract][Full Text] [Related]
17. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
20. A label-free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P
Grailhe P; Boutarfa-Madec A; Beauverger P; Janiak P; Parkar AA
FEBS Open Bio; 2020 Oct; 10(10):2010-2020. PubMed ID: 32810927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
